上海医药
(601607)
| 流通市值：468.87亿 | | | 总市值：623.38亿 |
| 流通股本：27.89亿 | | | 总股本：37.08亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 32,397,404,805.7 | 36,572,968,513.83 | 31,212,245,657.38 | 32,721,763,351.58 |
| 交易性金融资产 | 9,854,338,993.56 | 9,416,880,703.56 | 9,904,370,812.87 | 10,360,938,931.51 |
| 衍生金融资产 | 4,934,266.39 | 7,530,453.55 | 80,274.74 | 721,010.06 |
| 应收票据及应收账款 | 95,379,164,217.97 | 91,579,082,598.68 | 91,981,694,328.42 | 83,336,971,509.14 |
| 其中：应收票据 | 858,204,606.32 | 811,204,037.83 | 831,905,512.76 | 1,030,570,879.31 |
| 应收账款 | 94,520,959,611.65 | 90,767,878,560.85 | 91,149,788,815.66 | 82,306,400,629.83 |
| 应收款项融资 | 2,397,128,705.92 | 1,942,680,670.9 | 1,874,956,792.4 | 2,528,730,548.02 |
| 预付款项 | 1,782,188,982.13 | 1,474,185,217.36 | 2,060,988,961.4 | 1,621,546,115.42 |
| 其他应收款合计 | 2,847,212,748.12 | 3,466,234,473.71 | 2,921,383,716.98 | 3,113,104,316.93 |
| 应收股利 | 41,282,898.66 | 41,282,898.66 | 18,742,898.66 | 18,742,898.66 |
| 存货 | 43,380,898,236.17 | 42,684,986,108.4 | 41,681,805,607.04 | 45,358,947,550.04 |
| 一年内到期的非流动资产 | 64,303,477.33 | 103,838,480.76 | 51,052,945.98 | 87,403,889.78 |
| 其他流动资产 | 1,133,150,488.02 | 1,133,063,640.33 | 1,152,864,021.04 | 1,333,568,015.3 |
| 流动资产合计 | 189,240,724,921.31 | 188,381,450,861.08 | 182,841,443,118.25 | 180,463,695,237.78 |
| 非流动资产: | | | | |
| 长期应收款 | 265,172,166.94 | 279,918,426.65 | 342,693,723.21 | 307,934,020.34 |
| 长期股权投资 | 7,286,071,080.64 | 6,965,584,305.64 | 7,037,227,345.15 | 7,010,202,458.66 |
| 其他权益工具投资 | 28,413,976.9 | 20,954,561.79 | 24,026,623.59 | 32,683,905.48 |
| 其他非流动金融资产 | 1,468,806,835.65 | 1,447,832,164.69 | 1,549,962,438.2 | 1,545,310,713.45 |
| 投资性房地产 | 341,777,249.28 | 384,867,643.19 | 361,866,216.01 | 411,930,954.28 |
| 固定资产 | 15,836,173,712.77 | 15,292,222,316.37 | 15,223,546,056.78 | 15,493,395,192.45 |
| 在建工程 | 1,490,288,037.11 | 1,965,059,575.33 | 2,081,774,632.17 | 1,994,094,180.71 |
| 生产性生物资产 | 5,328,833.17 | 5,602,950.32 | 5,751,402.87 | 4,774,514.95 |
| 使用权资产 | 2,062,834,308.31 | 2,011,573,780.5 | 1,932,708,925.01 | 1,793,806,208.1 |
| 无形资产 | 8,382,215,824.41 | 8,498,378,931.44 | 8,632,619,257.63 | 8,743,750,239.23 |
| 开发支出 | 96,164,174.99 | 92,274,735.55 | 102,871,193.91 | 103,244,846.29 |
| 商誉 | 12,652,019,687.62 | 12,652,944,172.72 | 12,666,528,950.87 | 12,665,615,569.87 |
| 长期待摊费用 | 481,590,493.17 | 509,757,083.34 | 527,728,780.55 | 546,294,913.19 |
| 递延所得税资产 | 2,046,528,272.13 | 1,864,369,354.88 | 1,692,445,192.66 | 1,640,049,019.47 |
| 其他非流动资产 | 363,195,042.8 | 396,627,585.74 | 346,289,831.38 | 391,984,792.96 |
| 非流动资产合计 | 52,806,579,695.89 | 52,387,967,588.15 | 52,528,040,569.99 | 52,685,071,529.43 |
| 资产总计 | 242,047,304,617.2 | 240,769,418,449.23 | 235,369,483,688.24 | 233,148,766,767.21 |
| 流动负债: | | | | |
| 短期借款 | 44,736,265,429.87 | 46,528,516,265.24 | 46,702,003,108.98 | 44,091,821,016.96 |
| 衍生金融负债 | 20,248,976.43 | 18,954,922.41 | 18,878,426.51 | 13,294,428.53 |
| 应付票据及应付账款 | 66,790,447,919.42 | 63,584,650,213.43 | 62,355,517,360.44 | 61,404,558,255.56 |
| 其中：应付票据 | 7,851,713,440.22 | 6,979,977,892.1 | 9,024,741,044.08 | 8,810,206,222.12 |
| 应付账款 | 58,938,734,479.2 | 56,604,672,321.33 | 53,330,776,316.36 | 52,594,352,033.44 |
| 合同负债 | 1,208,870,642.88 | 1,190,757,061.89 | 1,161,049,807.59 | 1,504,248,413.81 |
| 应付职工薪酬 | 1,674,937,738.56 | 1,699,845,354.02 | 1,472,233,748.3 | 1,922,236,416.36 |
| 应交税费 | 1,502,802,061.06 | 1,449,580,785.89 | 1,324,994,987.02 | 1,486,244,282.39 |
| 其他应付款合计 | 16,671,126,353.22 | 18,092,756,678.9 | 16,061,134,297.36 | 16,731,913,987.12 |
| 应付股利 | 635,932,163.51 | 1,838,911,496.65 | 544,257,913.2 | 1,074,213,335.02 |
| 一年内到期的非流动负债 | 1,674,738,606.98 | 1,703,541,380.83 | 2,168,532,783.96 | 2,809,599,313.1 |
| 其他流动负债 | 6,230,712,533.17 | 6,153,140,784.01 | 5,244,289,163.87 | 5,234,190,156.67 |
| 流动负债合计 | 140,510,150,261.59 | 140,421,743,446.62 | 136,508,633,684.03 | 135,198,106,270.5 |
| 非流动负债: | | | | |
| 长期借款 | 3,357,311,273.75 | 3,277,066,729.23 | 3,257,225,265.34 | 4,235,875,600.03 |
| 租赁负债 | 1,502,908,595.69 | 1,473,819,650.08 | 1,462,573,484.66 | 1,149,374,250.76 |
| 长期应付款 | 9,000,000 | 9,000,000 | 9,000,000 | 9,000,000 |
| 长期应付职工薪酬 | 43,668,781.67 | 41,578,510.09 | 45,276,033.02 | 43,678,918.22 |
| 预计负债 | 78,326,925.85 | 69,615,676.72 | 79,108,102.85 | 74,699,932.37 |
| 递延收益 | 546,412,221.88 | 576,986,019.26 | 551,504,627.18 | 573,376,479.16 |
| 递延所得税负债 | 1,920,398,888.48 | 1,984,063,259.81 | 1,827,835,209.29 | 1,945,081,137.22 |
| 其他非流动负债 | 153,756,236.41 | 129,765,338.66 | 160,809,031.42 | 132,280,455.35 |
| 非流动负债合计 | 7,611,782,923.73 | 7,561,895,183.85 | 7,393,331,753.76 | 8,163,366,773.11 |
| 负债合计 | 148,121,933,185.32 | 147,983,638,630.47 | 143,901,965,437.79 | 143,361,473,043.61 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 3,708,361,809 | 3,708,361,809 | 3,708,361,809 | 3,708,361,809 |
| 资本公积 | 30,208,731,819.24 | 29,970,316,212.43 | 29,697,956,364.44 | 29,687,120,114.88 |
| 其他综合收益 | -519,269,028.34 | -566,060,526.77 | -551,829,250.5 | -532,971,659.94 |
| 盈余公积 | 2,306,949,383.63 | 2,306,949,383.63 | 2,306,949,383.63 | 2,306,949,383.63 |
| 未分配利润 | 43,639,069,026.72 | 42,928,389,019.08 | 42,139,625,230.67 | 40,721,868,176.6 |
| 归属于母公司股东权益合计 | 79,343,843,010.25 | 78,347,955,897.37 | 77,301,063,537.24 | 75,891,327,824.17 |
| 少数股东权益 | 14,581,528,421.63 | 14,437,823,921.39 | 14,166,454,713.21 | 13,895,965,899.43 |
| 股东权益合计 | 93,925,371,431.88 | 92,785,779,818.76 | 91,467,518,250.45 | 89,787,293,723.6 |
| 负债和股东权益合计 | 242,047,304,617.2 | 240,769,418,449.23 | 235,369,483,688.24 | 233,148,766,767.21 |
| 公告日期 | 2026-10-30 | 2026-08-28 | 2026-04-30 | 2026-03-31 |
| 审计意见(境内) | | | | 标准无保留意见 |